Predict to Prevent Prognomixs vision is the development of personalized medicine for the early detection of susceptibilities to diseases their complications and individual therapeutic responsiveness using genomic signatures Their initial focus is the development of presymptomatic diagnostic tools of diabetic complications based on genomic signatures aimed at individualized targeted prevention
Missing: Prognomix's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Prognomix's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Prognomix
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Prognomix is included in 2 Expert Collections, including Diabetes.
Health Monitoring & Diagnostics
Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance
Latest Prognomix News
Dec 20, 2019
Summary Prognomix Inc Prognomix is a personalized medicine company that develops molecular diagnostic test for detection of risks to develop renal , ocular, cardiac, cerebral, vascular and other complications of diabetic disease. The company's products include PGX IR01, PGx GR01, PGx CD01, PGx IR02. Its PGx CD01 is an in vitro molecular companion diagnostic product used for the treatment of cardiovascular and renal complications of type 2 diabetes. Prognomix's PGX IR01 is an in vitro molecular predictive test used for assessing the risk of complications in patients with type 2 diabetes. The company also develops molecular diagnostic test for detection of risks to develop renal, ocular, cardiac, cerebral, vascular and other complications of diabetic disease. Prognomix is headquartered in Montreal, Quebec, Canada. This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Scope: The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments The report analyzes all pipeline products in development for the company Prognomix Inc The report provides pipeline analysis on all pipeline products of the company by equipment type, by indication, by development stage, and by trial status The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indications, applications and estimated launch date The report provides detailed description of products in development, technical specification and functions The report also covers ongoing clinical trials wherever applicable with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date. Reasons to Buy: Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio To formulate effective Research Development strategies Develop marketentry and market expansion strategies Exploit inlicensing and outlicensing opportunities by identifying products, most likely to ensure a robust return Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc Identify, understand and capitalize the next highvalue products that your competitor would add in its portfolio Note: Some sections may be missing if data is unavailable for the company Related Biotechnology, Pharmaceutical and Healthcare News
Prognomix Frequently Asked Questions (FAQ)
Where is Prognomix's headquarters?
Prognomix's headquarters is located at 4101 Rue Molson, Montreal.
What is Prognomix's latest funding round?
Prognomix's latest funding round is Other Investors.
Who are the investors of Prognomix?
Investors of Prognomix include BDC Venture Capital.
Who are Prognomix's competitors?
Competitors of Prognomix include Oxford BioDynamics, Decipher Biosciences, Capso Vision, Upromise, Exagen and 10 more.
Compare Prognomix to Competitors
At Nanogen, Inc., the company develop diagnostic products that enable physicians to deliver improved patient care. The company's products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These products include molecular diagnostic kits and reagents, and rapid test kits, which can be used in urgent care settings or at the point-of-care. Nanogen has pioneered developments in areas involving biomarkers, molecular biology and nanotechnology. The company's business focus is to bring better results to diagnostics and healthcare.
Civatech Oncology is a medical device company focused on the development of polymer based devices that treat cancer using localized, low-dose-rate radiation. The company's fabrication methods allow for precise encapsulation of radioactive materials into polymer structures. These polymer-based brachytherapy devices offer physicians treatment options for tumors with low-dose-rate brachytherapy.
CellPoint Diagnostics is developing diagnostic, monitoring, and molecular analytical tools for cancer. Its technology captures and analyzes circulating tumor cells ("CTCs") directly from patient blood. Scientific and clinical data have demonstrated that CTCs are derived from the primary tumor, and the assessment of the number of CTCs in the blood has been shown to accurately predict survival for cancer patients.
NeoDiagnostix develops molecular diagnostic and prognostic tests for the treatment of cancer. The company's test results eliminate the ambiguity experienced in millions of samples analyzed by traditional cytomorphology-based cell analyses. The company is committed to providing physicians with information that will improve patient care and treatment.
theraGenetics is a personalized medicine diagnostics company developing pharmacogenetic tests to guide and improve the treatment of central nervous system (CNS) disorders; matching the medication to the patient.
Daktari Diagnostics develops products that deliver critical diagnostic information to clinicians and patients. Daktari's initial product is a handheld CD4 cell counter that aims to enable CD4 counting to be done by anyone. The company intends to bring this blood test to parts of the world where millions of people now have access to life-saving drugs, yet cannot begin treatment due to inadequate diagnostics.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.